CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 8.36 HKD -0.71% Market Closed
Market Cap: 4.8B HKD
Have any thoughts about
CARsgen Therapeutics Holdings Ltd?
Write Note

CARsgen Therapeutics Holdings Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CARsgen Therapeutics Holdings Ltd
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Cash from Financing Activities
-ÂĄ22.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Financing Activities
ÂĄ2.6B
CAGR 3-Years
-57%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash from Financing Activities
ÂĄ2.1B
CAGR 3-Years
-34%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Financing Activities
-ÂĄ893.3m
CAGR 3-Years
N/A
CAGR 5-Years
-98%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Financing Activities
-ÂĄ2B
CAGR 3-Years
24%
CAGR 5-Years
-38%
CAGR 10-Years
-39%
Imeik Technology Development Co Ltd
SZSE:300896
Cash from Financing Activities
-ÂĄ1.4B
CAGR 3-Years
N/A
CAGR 5-Years
-98%
CAGR 10-Years
N/A
No Stocks Found

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
4.8B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
12.81 HKD
Undervaluation 35%
Intrinsic Value
Price

See Also

What is CARsgen Therapeutics Holdings Ltd's Cash from Financing Activities?
Cash from Financing Activities
-22.1m CNY

Based on the financial report for Dec 31, 2023, CARsgen Therapeutics Holdings Ltd's Cash from Financing Activities amounts to -22.1m CNY.

What is CARsgen Therapeutics Holdings Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
91%

Over the last year, the Cash from Financing Activities growth was 91%.

Back to Top